Login to Your Account



Seagen reaches for upper ECHELON with Adcetris in front-line advanced cHL

By Marie Powers
News Editor

Monday, December 11, 2017

ATLANTA – Forty years after the establishment of ABVD as standard-of-care front-line therapy in patients with previously untreated advanced cHL, Seattle Genetics Inc. revealed details supporting its contention that replacing bleomycin with Adcetris could improve efficacy and reduce toxicity.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription